| 发明名称 |
ApoIII and the Treatment and Diagnosis of Diabetes |
| 摘要 |
The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells. |
| 申请公布号 |
US2016041191(A1) |
申请公布日期 |
2016.02.11 |
| 申请号 |
US201514867523 |
申请日期 |
2015.09.28 |
| 申请人 |
BioCrine AB |
发明人 |
BERGGREN Per-Olof |
| 分类号 |
G01N33/92;C07K16/18;G01N33/50;C12N15/113 |
主分类号 |
G01N33/92 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of identifying candidate compounds for the treatment of diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration in the presence of one or more test compounds and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. |
| 地址 |
Stockholm SE |
